Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.33 USD
+0.10 (8.13%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $1.33 0.00 (0.00%) 5:30 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 1 - 20 ( 397 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department